# Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

> **NCT03127020** · PHASE2 · COMPLETED · sponsor: **PIQUR Therapeutics AG** · enrollment: 9 (actual)

## Conditions studied

- Lymphoma
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** PQR309

## Key facts

- **NCT ID:** NCT03127020
- **Lead sponsor:** PIQUR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2019-03-21
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-06-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03127020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03127020, "Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03127020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*